Addex Therapeutics ADXN Stock
Addex Therapeutics Price Chart
Addex Therapeutics ADXN Financial and Trading Overview
| Addex Therapeutics stock price | 6.4 USD |
| Previous Close | 6.65 USD |
| Open | 6.68 USD |
| Bid | 5.91 USD x 300 |
| Ask | 7.33 USD x 300 |
| Day's Range | 6.65 - 6.68 USD |
| 52 Week Range | 5.41 - 12.05 USD |
| Volume | 1.8K USD |
| Avg. Volume | 3.79K USD |
| Market Cap | 8.42M USD |
| Beta (5Y Monthly) | 1.982 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.16 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ADXN Valuation Measures
| Enterprise Value | 981.48M USD |
| Trailing P/E | N/A |
| Forward P/E | -133 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 48.697575 |
| Price/Book (mrq) | 1.357549 |
| Enterprise Value/Revenue | 5677.876 |
| Enterprise Value/EBITDA | -348.762 |
Trading Information
Addex Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.982 |
| 52-Week Change | -17.69% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 12.05 USD |
| 52 Week Low | 5.41 USD |
| 50-Day Moving Average | 6.67 USD |
| 200-Day Moving Average | 7.84 USD |
ADXN Share Statistics
| Avg. Volume (3 month) | 3.79K USD |
| Avg. Daily Volume (10-Days) | 1.76K USD |
| Shares Outstanding | 1.27M |
| Float | 117.58M |
| Short Ratio | 1.09 |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.045% |
| Shares Short | 5.01K |
| Short % of Float | 0.45% |
| Short % of Shares Outstanding | 0.40% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -4922.69% |
| Gross Margin | -287.99% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -20.64% |
| Return on Equity (ttm) | -94.74% |
Income Statement
| Revenue (ttm) | 172.86K USD |
| Revenue Per Share (ttm) | 0.24 USD |
| Quarterly Revenue Growth (yoy) | 949.70% |
| Gross Profit (ttm) | -497821 USD |
| EBITDA | -2814174 USD |
| Net Income Avi to Common (ttm) | -6842588 USD |
| Diluted EPS (ttm) | -9.18 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.64M USD |
| Total Cash Per Share (mrq) | 0.01 USD |
| Total Debt (mrq) | 34.69K USD |
| Total Debt/Equity (mrq) | 0.73 USD |
| Current Ratio (mrq) | 1.401 |
| Book Value Per Share (mrq) | 4.8985343 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -2171117 USD |
| Levered Free Cash Flow (ttm) | -1267405 USD |
Profile of Addex Therapeutics
| Country | United States |
| State | N/A |
| City | Geneva |
| Address | Chemin des Mines, 9 |
| ZIP | 1202 |
| Phone | 41 22 884 1555 |
| Website | https://www.addextherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Q&A For Addex Therapeutics Stock
What is a current ADXN stock price?
Addex Therapeutics ADXN stock price today per share is 6.4 USD.
How to purchase Addex Therapeutics stock?
You can buy ADXN shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Addex Therapeutics?
The stock symbol or ticker of Addex Therapeutics is ADXN.
Which industry does the Addex Therapeutics company belong to?
The Addex Therapeutics industry is Biotechnology.
How many shares does Addex Therapeutics have in circulation?
The max supply of Addex Therapeutics shares is 1.27M.
What is Addex Therapeutics Price to Earnings Ratio (PE Ratio)?
Addex Therapeutics PE Ratio is now.
What was Addex Therapeutics earnings per share over the trailing 12 months (TTM)?
Addex Therapeutics EPS is -9.16 USD over the trailing 12 months.
Which sector does the Addex Therapeutics company belong to?
The Addex Therapeutics sector is Healthcare.
Addex Therapeutics ADXN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}